Evidence map›Paper›PMID 42034602›Full record

ArticleCell death & disease2026

TCHP drives hepatocarcinogenesis through LLPS-mediated AURKA condensation and enables synergistic therapy.

Jingshi Li, Yan Li, Xilang Pan, Shu Wang, Zaisheng Lin, Ruida He, Suning Wang, Xin Huang, Jia-Qi Li, Zhiwei Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jingshi Li *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Yan Li *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Xilang Pan *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Shu Wang *Department of Biochemistry and Molecular Cell Biology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zaisheng Lin *Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Ruida HePrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Suning WangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Xin HuangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Jia-Qi LiDepartment of Gastroenterology, Children's Hospital of Soochow University, Suzhou, China.
Zhiwei ZhangDepartment of Oncology, Affiliated Hospital of Hebei University of Engineering, Handan, China.
Liang WangSchool of Life Sciences, Jiangsu Normal University, Xuzhou, China.
Xiujuan ZhangPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China. zhangxj123@sjtu.edu.cn.
Xuxu SunDepartment of Biochemistry and Molecular Cell Biology, State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China. xuxu.sun@shsmu.edu.cn.
Muqing CaoPrecision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; Department of Pathophysiology, College of Basic Medical Sciences, Shanghai Jiao Tong University, Shanghai, China. muqingcao@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-0352-6548

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32170609National Natural Science Foundation of China (National Science Foundation of China) 32322021 and 32570808
6 · The paper itself

Abstract

Liver cancer is a leading cause of cancer-related death worldwide. Centrosomal proteins play critical roles in maintaining mitotic fidelity, and their dysregulation contributes to tumorigenesis. Trichoplein (TCHP), a centrosomal protein has recently been implicated in cell cycle progression, but its role in liver cancer remains unclear. In this study, we demonstrate that TCHP is markedly upregulated in hepatocellular carcinoma and hepatoblastoma and is associated with poor patient survival. Functional analyses revealed that TCHP overexpression accelerates hepatocarcinogenesis in mice, while its depletion suppresses tumor growth by inducing mitotic defects and extensive tumor cell death. Mechanistically, TCHP safeguards mitotic fidelity by localizing to centrosomes and promoting liquid-liquid phase separation-driven condensate formation with AURKA, thereby enhancing its activation. Importantly, TCHP inhibition not only suppresses tumor growth directly but also sensitizes liver cancer cells to the AURKA inhibitor alisertib, allowing tumor suppression at reduced drug doses and mitigating toxicity risks. Collectively, our findings establish TCHP as a potential oncogenic driver and therapeutic vulnerability in liver cancer and highlight the TCHP-AURKA axis as a promising target for synergistic treatment strategies.

Indexed as

Aurora Kinase ACarcinogenesisCarcinoma, HepatocellularCentrosomal Associated ProteinsLiver NeoplasmsAnimalsAzepinesCell Line, TumorCentrosomeHumansMicePyrimidinesAURKA protein, humanAurora Kinase AAzepinesCentrosomal Associated ProteinsMLN 8237Pyrimidines

Identifiers

PMID42034602
PMCPMC13247272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.